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“Le hasard ne favorise que les esprits préparés” 
Louis PASTEUR 
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ABSTRACT 
 
Platelet-derived growth factors PDGFs are a family of ligands and receptors that regulate 
multiple processes of paramount importance during embryonic development. They are also 
involved in several pathological events, spanning from tumours to fibrotic diseases. PDGFs have 
been studied for more than 30 years, but the mechanisms, as well as the tissue and cell type 
specific physiological roles of PDGF biology are still not fully understood. 
The work presented in this thesis investigates the role of PDGFR-alpha in cell differentiation 
during cardiac tissue specification, and the effects of PDGF overexpression in the myocardium 
during development and in the context of cardiac injury. We also examine the elusive function of 
the PDGF-A retention motif in PDGFR-alpha signalling during morphogenesis. The adoption 
of a reporter construct knocked into the PDGFR-alpha locus allowed us to precisely follow its 
site of expression. 
Here we report evidence of a role for PDGFR-alpha signalling in the recruitment and 
differentiation of second heart field-derived cells during cardiac inflow tract development (paper 
I).  
We also studied of the physiological role of the PDGF-A retention motif and the effects of its 
ablation. This work points to a preponderant role for the diffusible isoform in PDGFR-alpha 
signalling (paper II). 
The data presented in paper III investigate the effects of PDGF-A and PDGF-B overexpression 
in the developing mouse myocardium, and complements  previously published reports on 
PDGF-C and PDGF-D overexpression in the same system. Our findings extend the evaluation 
of the role of PDGFs in myocardial fibrosis induction, and suggest PDGFR-alpha positive cells 
as the source of excessive extracellular matrix deposition in the heart in response to ectopic 
PDGF expression. 
Ectopic expression of the different PDGF ligands in injured and inflamed cardiac tissue reveals 
an unexpected role for PDGFs in tissue recovery, that appears to be mediated by PDGFR-alpha 
signalling cells (paper IV). 
Many questions remain open-ended regarding PDGF signalling. The work presented in this 
thesis points at new and interesting directions for future studies. 
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1 INTRODUCTION 
 
HEART DEVELOPMENT AND NKX 2.5 EXPRESSION 
 
The murine heart development is dependent on many different proteins, the most important of 
which is perhaps Nkx 2.5. Nkx 2.5 is the vertebrate homologue of Drosophila tinman homeobox 
transcription factor, the first driver of cardiac specification (Bodmer 1993; Lints, Parsons et al. 
1993; Chen and Schwartz 1995; Stanley, Biben et al. 2002). 
Nkx 2.5 positive cardiac progenitor cells get localized in the lateral anterior mesoderm during late 
gastrulation (E7) (Garcia-Martinez and Schoenwolf 1993; reviewed by Schoenwolf and Garcia-
Martinez 1995; Tam, Parameswaran et al. 1997). At E7.5 these groups of cells converge at the 
midline and form the cardiac crescent (Redkar, Montgomery et al. 2001) (Figure 1). The midline 
has been perceived as a source of induction of gradient (Davis, Edwards et al. 2001; Kelly, 
Brown et al. 2001), with Notch signalling as key regulator of fate restriction (Raffin, Leong et al. 
2000; Rones, McLaughlin et al. 2000). 
 
 
Figure 1: Two sources of myocardial cells in the developing heart. Myocardial cells in the mouse embryo. The 
location and contribution of the second heart field is shown in green, compared with the myocardial cells that are 
derived from the first heart field (shown in red). The lineage contributions to the heart at E8.5 are summarized with 
the same colour coding. LA, left atria; LV, left ventricle; OFT, outflow tract; PA, primitive atria; PhA, pharyngeal 
arches; RA, right atrium; RV, right ventricle; 1, outflow region; 2, primitive right ventricle; 3, primitive left ventricle; 
4/5, atrioventricular region; 6/7, primitive left and right atria (modified, with permission, from Stainier 2001). 
 
At the cardiac crescent stage, between E7 and E8, Notch signalling resolves the fate of the 
progenitors, and we can witness the heart morphogenetic fields formation (Rones, McLaughlin 
et al. 2000). The first heart field progenitors are located ventrally, and they keep on expressing 
Nkx 2.5; they represent the main myogenic source for the left ventricle. The second heart field is 
located dorsally, and is characterized by Isl1 expression. These cells will be a second source of 
myocardium for the outflow tract and inflow tract, for the atria, and for the right ventricle 
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(Webb, Brown et al. 1998; Kelly, Brown et al. 2001; Mjaatvedt, Nakaoka et al. 2001; Waldo, 
Kumiski et al. 2001; Zaffran, Kelly et al. 2004; Moretti, Caron et al. 2006) (figure 1). Beside 
myocardium, second heart field progenitors can give rise to endothelial and smooth muscle cells 
(Moretti, Caron et al. 2006). The presence of common ontological mechanisms giving rise to 
inflow and outflow tract at the opposite poles of the heart primordia seems to be confirmed by 
many conotruncal defects common to the two regions in pathological situations (Bajolle, Zaffran 
et al. 2009). 
At around E8 the primordial heart tube closes, and the heart mesoderm splits into inner 
endocardial tube (endothelial cells) and surrounding myocardial cells. The process is regulated by 
Notch signalling, fibronectin gradient interaction, retinoic acid concentration, and endoderm 
differentiation itself (Linask and Lash 1993; Eisenberg and Bader 1995; Narita, Bielinska et al. 
1997; reviewed by Stainier 2001; reviewed by Harvey 2002). 
At E8.5 the left ventricular myocardium expands, the heart loops (reviewed by Eisenberg and 
Markwald 1995; Christoffels, Habets et al. 2000; Christoffels, Hoogaars et al. 2004) and the 
endocardium forms the cardiac cushion by epithelial to mesenchymal transition (Markwald, 
Fitzharris et al. 1977). By E10.5 the heart has acquired its four chambers structure, and by E14.5 
it has septa and is divided in four separate chambers (Christoffels, Habets et al. 2000; Moorman, 
Schumacher et al. 2000; reviewed by Harvey 2002). The curvature of the heart tube seems to be 
an inducer of transcriptional regulation (Manner, Seidl et al. 1993; reviewed by Harvey 2002), 
and, once again, Nkx 2.5 seems to be a key player in the process (Lyons, Parsons et al. 1995; 
Biben and Harvey 1997; Tanaka, Chen et al. 1999; Palmer, Groves et al. 2001), together with 
matrix components (Camenisch, Spicer et al. 2000). The complex valves and septa patterning 
seems to follow ontological sequential differentiation processes that recapitulate the phylogenetic 
development of the cardiac structures (Cai, Liang et al. 2003; Meilhac, Esner et al. 2004; Zaffran, 
Kelly et al. 2004). 
Around E8.5 also the proepicardial serosa develops from extracardiac tissue characterized by 
coelomatic markers like WT1 and RALDH2 (Moore, McInnes et al. 1999; Carmona, Gonzalez-
Iriarte et al. 2001). This tissue is the source of epicardial cells and all the cellular elements of the 
cardiac connective tissue (subepicardial and intermyocardial cells) (Manner 1993). The 
progenitors of all these cell types (smooth muscle cells and fibroblasts) share the same 
coelomatic markers (Mikawa and Gourdie 1996; Vrancken Peeters, Gittenberger-de Groot et al. 
1999; reviewed by Manner, Perez-Pomares et al. 2001; Cai, Liang et al. 2003; Zhou, Ma et al. 
2008). A contribution to the coronary endothelium is controversial (Mikawa and Gourdie 1996; 
Guadix, Carmona et al. 2006; reviewed by Riley and Smart 2011). The epicardium provides key 
signalling required for correct myocardial development (Chen, Chang et al. 2002; Perez-Pomares, 
Phelps et al. 2002; Stuckmann, Evans et al. 2003; Kang, Gu et al. 2008) (figure 2). 
The fundamental importance of Nkx 2.5 expression during heart development has been 
highlighted by loss of function studies, which demonstrate a nuance of defects depending on 
mutation site and time of induction. The defects include septation abnormalities between atria 
(Schott, Benson et al. 1998), looping failure (reviewed by Harvey 1996), and conduction system 
dysfunction (Schott, Benson et al. 1998; Pashmforoush, Lu et al. 2004). Moreover, Nkx 2.5 needs 
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to be downregulated for the correct development of the venous pole (Christoffels, 
Mommersteeg et al. 2006; Gittenberger-de Groot, Mahtab et al. 2007; Douglas, Mahtab et al. 
2009; Mahtab, Vicente-Steijn et al. 2009). 
 
  
Figure 2: Proepicardial organ. Scanning electron microscope micrographs showing the heart loop and the right 
horn of the sinus venosus from caudal direction. From the proepicardial organ, the primitive epicardium spreads as a 
continuous epithelial sheet over the naked myocardial surface (asterisk). A = Primitive atrium; V = ventricular loop; 
P = proepicardial organ; LI = liver. Scale bars = 200 μm (modified, with permission, from Manner, Perez-Pomares 
et al. 2001). 
 
There has been growing evidence pointing to a role for PDGF signalling in heart development. 
The initial studies of PDGF expression (Van Den Akker, Lie-Venema et al. 2005) and PDGF 
loss of function (Leveen, Pekny et al. 1994; Soriano 1997; Hellstrom, Kalen et al. 1999; Tallquist 
and Soriano 2003; Bjarnegard, Enge et al. 2004) related the heart defects observed to impaired 
contribution of neural crest cells for PDGFR-alpha signalling (Soriano 1997; Tallquist and 
Soriano 2003), and to coronary arteries maturation for PDGFR-beta signalling (Leveen, Pekny et 
al. 1994; Hellstrom, Kalen et al. 1999; Bjarnegard, Enge et al. 2004). The molecular mechanisms 
remained unclear until the cardiac defects seen in PDGF-B/PDGFR-beta loss of function were 
traced back to to impairment in the contribution of epicardial-derived cells (Van den Akker, 
Winkel et al. 2008). The key role for PDGFR-alpha signalling in epicardium development and 
epicardial-derived cell maturation remained undetected until our contribution to the field (Bax, 
Lie-Venema et al. 2009; Bax, Bleyl et al. 2010). 
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PDGF FAMILY SIGNALLING 
 
The first Platelet-derived growth factor ligands were identified through their proliferative effect 
on fibroblasts (Balk 1971). The main source of these growth factors has been identified as 
platelets (from which they derive their name), and their mitotic effect on fibroblasts (Kohler and 
Lipton 1974), smooth muscle cells (Ross, Glomset et al. 1974) and glial cells (Westermark and 
Wasteson 1976) emerged very quickly. After the first purification of PDGFs (Heldin, 
Westermark et al. 1979; Antoniades 1981), two peptides were identified: PDGF-A and PDGF-B 
(Johnsson, Heldin et al. 1982; Betsholtz, Johnsson et al. 1986). It was soon discovered that 
PDGF-A existed in two different splice variants (Bonthron, Morton et al. 1988; Rorsman, 
Bywater et al. 1988), with different relative abundance in different cell types (Matoskova, 
Rorsman et al. 1989). Other two ligands have been discovered more recently, in a quest for 
VEGF growth factor homologues: PDGF-C (Kazlauskas 2000; Li, Ponten et al. 2000) and 
PDGF-D (Bergsten, Uutela et al. 2001; LaRochelle, Jeffers et al. 2001). 
The first PDGF receptor identified was PDGFR-alpha (Heldin, Westermark et al. 1981). 
PDGFR-beta was identified by sequence similarity (Matsui, Heidaran et al. 1989). The structure 
analysis revealed their Tyrosine Kinase Receptor nature and the ligands interaction mechanisms 
(Claesson-Welsh, Eriksson et al. 1989). 
The ligands are secreted as dimers, linked by disulfide bonds, in 5 possible combinations: PDGF-
AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD (reviewed by Betsholtz, Karlsson et al. 
2001; reviewed by Andrae, Gallini et al. 2008). Their expression pattern is regulated differently in 
the various tissues and cell types, and the expression of PDGF-A and PDGF-B does not overlap 
(reviewed by Hoch and Soriano 2003). PDGF-A and PDGF-B are released as active dimers, 
while PDGF-C and PDGF-D require proteolytical processing of their CUB domains in order to 
bind the receptors (Li, Ponten et al. 2000; Bergsten, Uutela et al. 2001). 
Upon ligand binding, the receptors dimerize and are auto-phosphorylated at their intracellular 
domain (Kelly, Haldeman et al. 1991). The intracellular phosphorylation creates docking sites for 
signal transduction mediator proteins, most of which bind the phospho-tyrosines through their 
SH2 domains. The downstream signalling can influence cytoskeleton organization and gene 
transcription (reviewed by Heldin, Wasteson et al. 1985; Kazlauskas and Cooper 1989; reviewed 
by Claesson-Welsh 1994; reviewed by Kazlauskas 1994; Fambrough, McClure et al. 1999; 
reviewed by Heldin and Westermark 1999; reviewed by Betsholtz, Karlsson et al. 2001). The 
ligands bind the different receptors with different affinity, and in vitro studies have demonstrated 
that PDGFR-alpha can bind to PDGF-A, PDGF-C and PDGF-B with high affinity, while 
PDGFR-beta can bind with high affinity to PDGF-B and PDGF-D (Claesson-Welsh, Eriksson 
et al. 1989; Matsui, Heidaran et al. 1989; reviewed by Heldin and Westermark 1999; Kazlauskas 
2000; Li, Ponten et al. 2000; Bergsten, Uutela et al. 2001; LaRochelle, Jeffers et al. 2001). In vivo, 
only the interactions between PDGF-A, PDGF-C and PDGFR-alpha, and PDGF-B and 
PDGFR-beta have been confirmed, by loss of function studies (Morrison-Graham, Schatteman 
et al. 1992; Leveen, Pekny et al. 1994; Soriano 1994; Bostrom, Willetts et al. 1996; Lindahl, 
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Johansson et al. 1997; Lindahl, Karlsson et al. 1997; Soriano 1997; Hellstrom, Kalen et al. 1999; 
Karlsson, Lindahl et al. 2000; Price, Thielen et al. 2001; Bostrom, Gritli-Linde et al. 2002; 
Hamilton, Klinghoffer et al. 2003; Ding, Wu et al. 2004; reviewed by Andrae, Gallini et al. 2008) 
(figure 3). 
 
Figure 3: PDGF–PDGFR interactions. The first panel shows the interactions that have been demonstrated in cell 
culture. Hatched arrows indicate weak interactions or conflicting results. The second panel shows interactions 
proven to be of importance in vivo during mammalian development (modified, with permission, from Andrae, 
Gallini et al. 2008). 
 
The expression patterns and loss of function phenotypes of growth factors and receptors have 
been extensively studied in vivo. PDGFR-alpha is expressed by mesenchymal cells in general, by 
mesenchymal progenitors in lung, intestine, skin, heart, and by oligodendrocyte precursors 
(Morrison-Graham, Schatteman et al. 1992; Orr-Urtreger, Bedford et al. 1992; Orr-Urtreger and 
Lonai 1992; Palmieri, Payne et al. 1992; Schatteman, Morrison-Graham et al. 1992; Soriano 1997; 
Price, Thielen et al. 2001; Bax, Lie-Venema et al. 2009; Smith, Baek et al. 2011). The PDGFR-
alpha loss of function phenotype displays cleft face, sub-epidermal blistering, apoptosis of neural 
crest-derived mesenchyme, spina bifida, skeletal, vascular and cardiac defects (Morrison-Graham, 
Schatteman et al. 1992; Soriano 1997; Price, Thielen et al. 2001; Bax, Bleyl et al. 2010; Smith, 
Baek et al. 2011). PDGF-A and PDGF-C are expressed very early during embryonic 
development (blastocyst), and, in general, remain expressed by epithelial cells, muscle cells and 
neuronal progenitors (Mercola, Wang et al. 1990; Yeh, Ruit et al. 1991; Orr-Urtreger and Lonai 
1992; Palmieri, Payne et al. 1992; Ding, Wu et al. 2000; Durand and Raff 2000; Tallquist, 
Weismann et al. 2000). Loss of function studies evidenced specific roles for these two ligands: 
PDGF-A deletion reduced paraxial mesoderm development and dermal mesenchyme in skin, 
originates villus dys-morphogenesis in gut and emphysema pathologies in lungs, defects in testis, 
vertebrae, ribs, oligodendrocyte precursors population expansion and nerves myelination 
(Bostrom, Willetts et al. 1996; Lindahl, Karlsson et al. 1997; Calver, Hall et al. 1998; Fruttiger, 
Karlsson et al. 1999; Karlsson, Bondjers et al. 1999; Gnessi, Basciani et al. 2000; Karlsson, 
Lindahl et al. 2000; Bostrom, Gritli-Linde et al. 2002); PDGF-C deletion originates cleft palate 
and spina bifida (Ding, Wu et al. 2004), and cerebellar defects (Andrae et al., unpublished). 
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PDGFR-beta expression is observed in mesenchymal cells in tight contact with endothelial cells 
(vascular smooth muscle cells and pericytes) (Hellstrom, Kalen et al. 1999). Loss of function of 
this receptor results in cardiovascular complications like oedema, haemorrhages, heart and blood 
vessels dilation, abnormal kidney glomeruli, and hypoplasia of smooth muscle cells (Soriano 
1994; Hellstrom, Kalen et al. 1999). PDGF-B is expressed by vascular endothelial cells and 
megakaryocytes, especially in sprouting endothelia, in capillaries and in growing arteries (Lindahl, 
Johansson et al. 1997; Hellstrom, Kalen et al. 1999). Deletion of this growth factor produces the 
same phenotype observed in PDGFR-beta loss of function (Leveen, Pekny et al. 1994; Lindahl, 
Johansson et al. 1997; Hellstrom, Kalen et al. 1999). PDGF-D expression can be detected in 
fibroblasts and smooth muscle cells (Bergsten, Uutela et al. 2001; LaRochelle, Jeffers et al. 2001), 
but loss of function experiments for this ligand didn’t show any major phenotype (Eriksson, 
personal communication). 
The extracellular diffusion of the PDGF growth factors is strictly regulated: by proteolysis of the 
retention motif in PDGF-B (Ostman, Andersson et al. 1991), by alternative splicing for PDGF-
A (Ostman, Andersson et al. 1991; Pollock and Richardson 1992; Andersson, Ostman et al. 
1994; Fager, Camejo et al. 1995; Lustig, Hoebeke et al. 1996; Feyzi, Lustig et al. 1997), and 
probably by CUB domain processing for PDGF-C and PDGF-D (Li, Ponten et al. 2000; 
Bergsten, Uutela et al. 2001; reviewed by Betsholtz, Karlsson et al. 2001; reviewed by Andrae, 
Gallini et al. 2008). The possible function of these highly conserved extracellular-binding 
domains is the generation of gradients, a very important feature for growth factors signalling 
(Raines and Ross 1992; Kelly, Sanchez et al. 1993; reviewed by Betsholtz, Karlsson et al. 2001; 
reviewed by Andrae, Gallini et al. 2008; reviewed by Rogers and Schier 2011). The functional 
importance of the retention motif is well documented for PDGF-B (Abramsson, Lindblom et al. 
2003; Lindblom, Gerhardt et al. 2003; Abramsson, Kurup et al. 2007), but evidence for a specific 
role of the two splice variants of PDGF-A had been reported only for amphibians (Damm and 
Winklbauer 2011), until our study was published (Andrae, Ehrencrona et al. 2013). 
 
PDGFS IN WOUND HEALING AND FIBROSIS 
 
When a tissue gets injured, the epithelial and endothelial cells release inflammatory mediators and 
trigger a coagulation cascade. The thrombocytes circulating in the blood stream are activated by 
the interaction with exposed extracellular matrix components, like collagen and von Willebrand 
factor, present in the sub-endothelial layer. Prothrombin is then cleaved by proteolysis and 
generates thrombin, an enzyme that converts fibrinogen into its insoluble form of fibrin strands. 
Fibrin assists the thrombocytes in clumping, and together they form a fibrin clot that helps 
restoring haemostasis. The activated thrombocytes degranulate and release growth factors (like 
PDGF and TGF-beta1), cytokines and chemokines, which induce recruitment and proliferation 
of leukocytes and endothelial cells. The endothelial cells secrete matrix metalloproteinases that 
disrupt the basement membrane and increase the permeability of the tissue, facilitating the 
inflammatory cells migration to the injury site. The leukocytes recruited secrete growth factors 
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and cytokines that promote the amplification of the inflammatory reaction. Release of PDGFs 
and TGF-beta1 growth factors stimulates fibroblast proliferation and matrix deposition. TGF-
beta1 promotes also mesenchymal transition of epithelial and endothelial cells, which increases 
the fibroblast population. In the inflammatory context, fibroblasts become activated 
myofibroblasts, which express alpha-SMA and release cytokines in the wound, contributing to 
inflammation enhancement. The myofibroblasts migrate into the wounded tissue along the fibrin 
matrix, and assist wound contraction, pulling the edges of the injury towards the centre. In a 
normal situation the wound heals, with the epithelial and endothelial cells that proliferate and 
migrate over the basal layers to regenerate the damaged tissue, forming new blood vessel, and 
remodelling the extracellular matrix. If the inflammation persists and remains chronic, the 
accumulation of extracellular matrix components and the release of metalloproteinases inhibitors 
exceed the production of matrix metalloproteinases, and we can observe permanent fibrotic 
scarring and consequent organ malfunction. This unspecific and highly conserved healing 
process is common to all the different tissues, and it has been extensively recapitulated and 
reviewed in the last 30 years, thus I will refer the readers only to some of the most recent reviews 
on the topic (reviewed by Reinke and Sorg 2012; reviewed by Wynn and Ramalingam 2012; 
reviewed by Honda, Park et al. 2013) (figure 4). 
 
  
Figure 4: Outcomes of wound healing: tissue regeneration or fibrosis MMPS = matrix metalloproteinases; 
TIMPS = tissue inhibitors of metalloproteinases; EGF = epithelial growth factor; IL-6 = interleukin 6; IL-13 = 
interleukin 13; TNF= tumour necrosis factor; FGF = fibroblast growth factor; EMT = epithelial to mesenchymal 
transition; HSCs = hepatic stellate cells (with permission, from Wynn 2007). 
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The role of PDGF ligands and receptors has been investigated in fibrotic pathologies of many 
different tissues. In dermal fibrosis like scleroderma, increased expression of PDGFs and their 
receptors has been observed (Klareskog, Gustafsson et al. 1990; Kawaguchi, Hara et al. 1999; 
Distler, Jungel et al. 2007; Sonnylal, Denton et al. 2007; Olson and Soriano 2009). PDGFR-alpha 
signalling-dependent mesenchymal proliferation (Fellstrom, Klareskog et al. 1989) and PDGF-D 
upregulation (Ostendorf, van Roeyen et al. 2003; Ostendorf, Rong et al. 2006) have been linked 
to renal fibrosis, where inhibition of PDGF receptors has been reported to reduce inflammation 
(Chen, Chang et al. 2011). Hepatic fibrosis has been associated to upregulation of PDGFR-beta 
and PDGF-B (Pinzani, Milani et al. 1996; Borkham-Kamphorst, van Roeyen et al. 2007). An 
increase in PDGF-C expression has been detected in pulmonary fibrosis (Homma, Nagaoka et 
al. 1995; Rice, Moomaw et al. 1999; Zhuo, Zhang et al. 2004; Abdollahi, Li et al. 2005), where a 
reduction in fibrosis has been obtained with PDGF signalling inhibitors (Rhee, Lee et al. 2011). 
A key role for PDGFR-beta in vessel maturation and for PDGFR-alpha in fibroblast activation 
has been described in post infarct myocardial injury (Zymek, Bujak et al. 2006). Increased 
expression of PDGF-A, PDGF-B, PDGF-C and PDGF receptors has been reported for 
deoxycorticosterone-induced cardiac fibrosis (Ma, Li et al. 2012; Fan, Ma et al. 2013; Fan, Ma et 
al. 2014). 
Gain of function studies in pulmonary and cardiac tissues have demonstrated that PDGF-B 
overexpression originates focal areas of emphysema-like airspace expansion, inflammation and 
fibrosis in lung (Hoyle, Li et al. 1999), that PDGF-C and PDGF-D overexpression causes 
general and focal fibrosis respectively, in the myocardium (Ponten, Li et al. 2003; Ponten, 
Folestad et al. 2005), and that adenoviral-driven expression of PDGF-A, PDGF-C and PDGF-D 
accelerates fibrosis in cardiac allografts (Tuuminen, Nykanen et al. 2006). Our studies extend the 
investigation on the effects of ectopic expression of PDGFs in the cardiac tissue, adding the 
characterization of PDGF-A and PDGF-B overexpression in the myocardium, and a 
comparative study of the focal expression of all the PDGF ligands in cardiac injury (Gallini, 
Lindblom et al., unpublished, paper III in this thesis; Gallini, Huusko et al., unpublished, paper 
IV in this thesis). 
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2 THESIS AIM 
 
The aim of the work presented is to, literally, shed some more light (green and fluorescent) on 
the role of PDGFR-alpha signalling in developmental and pathological contexts. To do that, we 
utilized animals where a histone H2B-GFP fusion protein reporter construct was knocked into 
the PDGFR-alpha locus. This fusion protein allowed us to illuminate the PDGFR-alpha 
expression pattern, at a single cell resolution, in each of the studies presented in this thesis. 
In paper I we investigate the role of PDGFR-alpha signalling in the inflow tract and the second 
heart field-derived structures, in a PDGFR-alpha loss of function developmental study. 
In paper II we examine the physiological role of the evolutionarily conserved PDGF-A retention 
motif, and inquire how its ablation affects PDGFR-alpha signalling. 
Paper III explores the ability of PDGF-A and PDGF-B overexpression to cause fibrosis during 
cardiac development, as described for PDGF-C and PDGF-D. We inspect which of the two 
PDGF receptors is responsible for the signalling that leads to excessive extracellular matrix 
deposition. 
Paper IV looks into the involvement of the PDGF ligands in cardiac fibrosis in adult 
myocardium, and explores the role these growth factors play in cardiac injury. 
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3 METHODS 
 
PDGFR-alpha knock-in tool: we used mice expressing histone H2B-GFP fusion protein reporter 
construct knocked into the PDGFR-alpha locus (Hamilton, Klinghoffer et al. 2003), in order to 
identify and follow cells expressing PDGFR-alpha. 
 
Generation of transgenic mice: the DNA we wanted to modify was subcloned and modified by 
site-specific mutagenesis and enzymatic restriction. The DNA constructs to integrate into the 
genome by homologous recombination were either microinjected into fertilized oocytes 
pronuclei (paper III), or transfected by electroporation into ES cells (paper II). The ES cells were 
then injected into blastocysts. The oocytes or the blastocysts were in the end transplanted into 
pseudopregnant females to generate gene-targeted mice. 
 
Echocardiography: this technique applies high frequency sound waves to create an image of the 
heart, and, by Doppler effect application, allows the determination of blood flow speed and 
direction. Estimation of the heart performance can be obtained from cardiac output, ejection 
fraction and diastolic function data. We used a high-resolution imaging system especially 
developed for small animal research. The transducer was placed on one side of the mouse thorax 
after shaving, while the animals were anaesthetized with isoflurane (paper IV). 
 
Adenovirus injections: the adenoviruses encoding for the PDGF ligands were injected into the 
ventricle wall of the mice under high-resolution echocardiography guidance. This method uses 
ultrasound imaging of the mouse heart to guide the injections, and allows the procedure to be 
performed on closed chest, avoiding the need for surgical visualization of the organ. 
 
Harvesting of embryos: in order to stage the embryos we crossed the animals overnight and 
checked for vaginal plugs the next morning, which was set as E0.5. The pregnant females were 
sacrificed at the desired embryonic day, the embryos were harvested and dissected under a 
dissection microscope, and fixed right away. We genotyped the embryos by PCR on yolk sacs or 
tail fragments, with specific primers (papers I, II, III). 
 
Immunohistochemistry: light microscopy can be used to examine the histology of different 
organs. To visualize specific molecules, paraffin-embedded samples are exposed to antibodies 
conjugated to enzymes that can catalyse a colour-producing reaction. The tissues are usually 
counterstained to provide contrast and identify cell nuclei and cellular bodies. 
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Quantification of lung alveolar density: in paper II we evaluated the number and perimeter of the 
open areas in lung’s alveolar network on bright field images of paraffin embedded tissues. 
 
Immunofluorescent staining: in this technique fluorescent-labelled antibodies are used to detect 
and visualize the location and distribution of the antigen-molecules in the tissue sample. 
 
Confocal microscopy: this technique uses laser point illumination of the sample and a pinhole in 
front of the detector to eliminate out of focus signal. Only the light from fluorescence in the 
optical section of the focal plane can be detected, and the thickness of the optical section is 
determined by the pinhole. The technique allowed us to obtain high-resolution pictures of tissue 
morphology, with the help of fluorescent-labelled antibodies, dyes and transgenic expression of 
fluorescent proteins. 
 
Quantification of cells in spinal cord: we needed to quantify the number of oligodendrocytes in 
the spinal cord in paper II. Consecutive transverse sections of embryo’s spinal cord were 
analysed by confocal microscopy. The ratio between PDGFR-alpha expressing cells (GFP 
labelled) and area was evaluated for each section and averaged along the spinal cord. 
 
Scar tissue analysis: in paper IV we evaluated the size of the injured cardiac tissue approximating 
it to an ellipsoid volume. The length of the axes was obtained by measurements in the two 
dimension confocal images and by recording thickness and number of the tissue sections. We 
also evaluated the PDGFR-alpha distribution in the injured area by imaging and counting GFP-
expressing cells. 
 
Morphometric analysis of myocardial volume: this is a method used to perform quantitative 
analyses of tissues. The AMIRA software system allows volumetric analysis in the three-
dimensional models, and we used it to evaluate the extension of several cardiac structures in 
paper I. 
 
Three-dimensional reconstruction of atrial and ventricular myocardium: in paper I we created 
three-dimensional models of heart tissue from microscope digital images, using the AMIRA 
software system. 
 
Epicardial cell isolation and cell culture: fragments of epicardial tissue were put in culture in 
paper I. The epicardial cells were obtained through cells outgrowth from the tissue fragments. 
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RNA interference: this method uses RNA molecules to inhibit gene expression by post-
transcriptional regulation. RNA molecules containing sequences complementary to the target 
mRNA cause its elimination. 
 
mRNA isolation and real-time PCR analysis: real-time PCR amplifies and quantifies the amount 
of a targeted DNA molecule. We detected the cDNA during the polymerase chain reaction 
progression with sequence-specific DNA probes, labelled with fluorophores that emit 
fluorescence only after hybridization. The amplification is carried out in special thermal cyclers 
that can illuminate the samples with specific wavelengths and detect the fluorescence emitted by 
the fluorophore. We used relative quantification methods to analyse gene-expression. We 
obtained the cDNA by reverse-transcription of mRNA. Our mRNA was prepared by spin 
column purification, where the mRNA extract is placed in a column and bound to its silica gel 
membrane by centrifugation. The gel membrane is then washed and eluted. The mRNA was 
retro-transcribed using random and oligo(dT) primers combined. 
 
Northern blotting: this method detects mRNA and determines its amount. The purified mRNA 
is separated by size by an electrophoresis gel run, and then transferred to a filter membrane and 
crosslinked. After blocking, the nucleic acid is detected by hybridization of a probe 
complementary to the target sequence. 
 
Western blotting: this method detects a protein and determines its size. The protein extract is 
loaded on polyacrylamide gel and size-fractioned by electrophoresis. The proteins are then 
transferred to a membrane by blotting, and detected by antibody staining after blocking. 
 
Analysis of albuminuria: albuminuria is a type of proteinuria where albumin is present in urine. 
The urine spots collected were loaded on polyacrylamide gel where the proteins were separated 
by electrophoresis. The gel was stained with a dye (Coomassie blue) that turns blue when bound 
to proteins, and the albumin band was identified and quantified in relation to bovine serum 
albumin standard (paper II). 
 
Statistics: the statistical significance of the experimental measurements was evaluated with 
independent sample (papers I, II, III) or paired (paper IV) Student’s t-test. 
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Ethical considerations: some of the experiments have been performed abroad. The animals 
kept in Sweden were bred and handled in accordance with Swedish animal welfare legislation, 
and all experiments were approved either by the Committee for Animal Ethics in Göteborg 
and in Stockholm North, or by the Animal Experiment Provincial Office in South Finland, or 
by the American Association for Laboratory Animal Science. 
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4 RESULTS AND DISCUSSION OF PRESENTED STUDIES  
 
PAPER I 
PDGFR-ALPHA IN SECOND HEART FIELD DEVELOPMENT 
 
When I made the first observations on PDGFR-alpha as a possible epicardial-derived cell marker 
in 2007, the outflow tract and septation defects reported for PDGFR-alpha null mutants and 
PDGF-A and PDGF-C double mutants had been ascribed to a failure in neural crest cells 
contribution (Schatteman, Motley et al. 1995; Ding, Wu et al. 2004; reviewed by Reigstad, 
Varhaug et al. 2005; Richarte, Mead et al. 2007). The research on epicardium and epicardial-
derived cells was focusing on PDGFR-beta, at that time (Van Den Akker, Lie-Venema et al. 
2005; Mellgren, Smith et al. 2008; Van den Akker, Winkel et al. 2008). Shortly after my 
preliminary observations, a role for PDGF-A/PDGFR-alpha signalling in epicardial cells 
proliferation has been reported (Kang, Gu et al. 2008), and we started a collaboration with prof. 
Adriana Gittemberger-de Groot’s group to investigate the specific role of PDGFR-alpha in 
second heart field contribution. The  first detailed analysis of the expression patterns of PDGF-
A, PDGF-C and PDGFR-alpha was performed in chicken embryos (Bax, Lie-Venema et al. 
2009), and confirmed my observations in mouse embryos. 
In the paper that I include in this thesis, we focus our attention on the inflow tract defects that 
originate in the absence of PDGFR-alpha signalling. Embryos carrying a PDGFR-alpha null 
mutation (knock-in with histone H2B-GFP fusion protein Hamilton, Klinghoffer et al. 2003) 
have been analysed from 9.5 to 14.5 days of embryonic development. The mutants show 
hypoplasia of the proepicardial organ, of the ventricular myocardium, and of the sinoarial node. 
Defects in ventricular and atrioventricular septation are also present, and the pulmonary vein fails 
to develop with the correct orientation. The epicardial-derived cells miss to efficiently migrate 
into the myocardium in the absence of PDGFR-alpha expression. The detailed analysis of Nkx 
2.5 expression revealed that this transcription factor remains expressed in the sinoatrial node, 
where it should be downregulated in order to allow the correct differentiation of the sinus 
venosus and the development of its pacemaker function (Pashmforoush, Lu et al. 2004; 
Blaschke, Hahurij et al. 2007; Espinoza-Lewis, Yu et al. 2009). 
Our discoveries indicate a key role for PDGFR-alpha in myocardial addition to the venous pole 
and in sinoatrial pacemaker development. The hypoplasia observed could be due to a direct role 
of PDGFR-alpha in second heart field’s epicardial cells differentiation (Prall, Menon et al. 2007), 
it could be ascribed to the lack of trophic signals from the epicardium to the myocardium (Perez-
Pomares, Phelps et al. 2002; Merki, Zamora et al. 2005; Kang, Gu et al. 2008; Lie-Venema, Eralp 
et al. 2008), or it could depend on partial heart tube looping failure (reviewed by Lie-Venema, 
van den Akker et al. 2007; Snarr, O'Neal et al. 2007; Snarr, Wirrig et al. 2007), as the pulmonary 
vein orientation and the mesenchymal cap and protrusion would suggest. 
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The ectopic expression of Nkx 2.5 infers a role for PDGFR-alpha in the homeodomain 
transcription factor repression. The misregulation in WT1 expression that we detected would 
also point in this direction, since WT1 has been shown to participate in epicardial-derived cells 
epithelial to mesenchymal transition through Snail (Martinez-Estrada, Lettice et al. 2010). The 
crucial role of PDGFR-alpha in epicardial to mesenchymal transformation has been described in 
relation to a specific subset of transcriptional inducers of epithelial to mesenchymal transition 
active in cardiac development (Smith, Baek et al. 2011), and this would explain why we observed 
differential regulation of the transcription factors that we analysed (alpha 4-integrin, VCAM and 
E-cadherin). 
Since defects in sinoatrial node and pulmonary vein connection are often related to conduction 
abnormalities (Korbmacher, Buttgen et al. 2001), it would be interesting to perform conduction 
and arrhythmia studies in hearts of epicardial specific PDGFR-alpha mutants. 
 
PAPER II 
PDGFR-ALPHA SIGNALING IN PDGF-A EXON6 KO MICE 
 
PDGF-A mRNA is transcribed into two alternative splicing isoforms: PDGF-AL includes exon 
6, which encodes for an 18 amino acids long carboxy-terminal heparin-binding motif; PDGF-AS 
does not include the transcript from exon 6, and its carboxy-terminal sequence is limited to the 3 
amino acids encoded by exon 7 (Betsholtz, Johnsson et al. 1986; Bonthron, Morton et al. 1988; 
Rorsman, Bywater et al. 1988). The presence of these isoforms is conserved across vertebrates, 
and the ability to bind heparin and heparan sulphate proteoglycans is common to many 
extracellular signalling proteins, where the presence of a retention motif has been linked to the 
ability to form gradients and boundaries (reviewed by Lin 2004; reviewed by Hacker, Nybakken 
et al. 2005; reviewed by Lindahl and Li 2009; reviewed by Rogers and Schier 2011). 
In this paper we investigated the physiological role of PDGF-AL. From our expression analysis, it 
emerged that PDGF-AS is the main component of secreted PDGF-A, with a minimal percentage 
of PDGF-AL. The highest absolute amount of PDGF-AL is present in lungs and intestine. With 
the approach applied to VEGF-A and PDGF-B retention motif studies in mind, we generated 
mutant mice homozygous for the deletion of the splice acceptor site in exon 6 of the pdgfa gene. 
These mice fail to produce the long isoform of PDGF-A, which binds to the extracellular matrix, 
and they only express the short, freely diffusible isoform PDGF-AS. These mutants have been 
named PDGF-A∆ex6/∆ex6. The mutation results in viable and fertile animals, that don’t show any 
obvious phenotype. We tried to challenge the mutants and limited the signalling trough PDGFR-
alpha, combining the PDGF-A∆ex6 mutation with PDGF-C null mutation PDGF-C-/-, or with 
heterozygous knocked-in receptor PDGFR-alphaGFP/+. PDGF-A∆ex6/-; PDGFR-alphaGFP/+ 
mutants develop progressive lung alveoli loss, and PDGF-A∆ex6/∆ex6; PDGF-C-/- animals display 
vertebral and intestinal defects. 
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We could not rule out a hypomorphic effect of the PDGF-A∆ex6 mutation, and the observed 
phenotypes could be the outcome of a dosage-dependent effect rather than being range 
dependent. 
What emerges from our study is that PDGFR-alpha signalling is probably a long range signalling 
in most of the physiological situations, and the main receptor/ligand interaction is carried out by 
the short isoform of PDGF-A. This interpretation would confirm what has been observed about 
PDGFR-alpha signalling in Xenopus gastrulation, where PDGF-AS is specifically required to 
guide directional migration of cells in the precordal mesoderm (Nagel, Tahinci et al. 2004; Damm 
and Winklbauer 2011). It would also comply with the fact that we can’t detect myelination 
defects on our mutants, in spite of the key role of PDGFR-alpha signalling on oligodendrocyte 
development (Calver, Hall et al. 1998; Fruttiger, Karlsson et al. 1999). The presence of PDGF-AS 
in our mutants would ensure the presence of a long range PDGFR-alpha signalling. 
Our approach of eliminating the long isoform of PDGF-A was inspired, as I mentioned, by the 
results obtained in the studies on PDGF-B and VEGF-A retention motifs, two growth factors 
whose short range signalling has fundamental implications in vessel morphogenesis and 
maturation (Ruhrberg, Gerhardt et al. 2002; Abramsson, Lindblom et al. 2003; Gerhardt, 
Golding et al. 2003; Lindblom, Gerhardt et al. 2003; Abramsson, Kurup et al. 2007). It would be 
interesting to study mutants lacking the possibility to splice out exon 6 of the pdgfa gene, and 
expressing only the long isoform of PDGF-A. Comparison of those mutants with PDGF-A null 
mutants could shed more light on the specific role of PDGF-AL and on the reasons for its 
conservation. 
 
PAPER III - PAPER IV 
PDGFR-ALPHA RESPONSE TO ECTOPIC EXPRESSION OF PDGF 
LIGANDS IN THE CARDIAC TISSUE 
 
PDGF signalling has been correlated to the onset of fibrosis in many different systems. These 
growth factors are documented mitogens and chemotactic agents for fibroblasts, and activate 
extracellular matrix deposition (Canalis 1981; Blatti, Foster et al. 1988; Schonherr, Jarvelainen et 
al. 1991; Fruttiger, Calver et al. 1996). In particular, they have been associated with cardiac 
fibrotic responses (Tuuminen, Nykanen et al. 2006; Ma, Li et al. 2012; Fan, Ma et al. 2013; Fan, 
Ma et al. 2014). 
We analysed the effect of ectopic expression of PDGF-A and PDGF-B during heart 
development in paper III, and the role of the different PDGF ligands in injury and inflammatory 
context in paper IV. 
In paper III we have generated and analysed transgenic mice, where PDGFs were overexpressed 
under the Myosin heavy chain-promoter, specific for cardiomyocyte development. The stable 
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and homogeneous expression of PDGF-A and -B in myocardium produces severe fibrosis, 
extensive hypertrophy and cardiac failure for PDGF-A gain of function, and focal fibrosis, 
correlated with moderate myocardial hypertrophy, for PDGF-B gain of function. These 
phenotypes can be directly compared to the effects of PDGF-C and PDGF-D gain of functions 
generated in the same transgenic system (Ponten, Li et al. 2003; Ponten, Folestad et al. 2005). In 
general we see fibroblast activation and abundant extracellular matrix deposition for each of the 
PDGF ligands ectopic expression (paper III, Ponten, Li et al. 2003; Ponten, Folestad et al. 2005). 
In paper IV we injected adenoviruses expressing the different PDGF isoforms into adult hearts 
of PDGFR-alphaGFP/+ mice. The focal and transient expression of the PDGF ligands by viral 
cDNA in such an inflammatory context has unpredicted effects: PDGFR-alpha agonists reduce 
the injury extension and recruit PDGFR-alpha positive cell population; PDGFR-beta agonists 
give rise to opposite reactions, with PDGF-B exacerbating inflammation without PDGFR-alpha 
cells recruitment, and with PDGF-D heavily reducing injury extension and inflammation. In each 
of the PDGF stimulation conditions we also witness Nkx 2.5 expression alteration. 
Our expression analysis in these systems suggests that PDGFR-alpha is a constant target for the 
signalling, and, possibly, the main receptor responsible for the final phenotypic outcomes, since 
we see enrichment in PDGFR-alpha positive cells, and they do not seem to co-express PDGFR-
beta. In line with this hypothesis, transgenic overexpression of PDGF-A gives a stronger fibrotic 
reaction than PDGF-B overexpression (paper III), and we detect more PDGFR-alpha positive 
cells recruited to the injury site in the virus-driven transient expression of PDFR-alpha agonists 
PDGF-A and PDGF-C (paper IV). PDGF-B has also been proved a potent PDGFR-alpha 
agonist in vitro (Hart, Forstrom et al. 1988; Heldin, Backstrom et al. 1988), but its transgenic 
expression in paper III gives rise to a milder fibrotic effect than PDGF-A and PDGF-C, and 
very similar to the effect of the PDGFR-beta agonist PDGF-D (Ponten, Folestad et al. 2005). 
The Nkx 2.5 expression responses in paper IV point at a role for PDGF signalling in cell fate 
determination, and it has been related to cardiac extracellular matrix remodelling (Sullivan, Quinn 
et al. 2014). 
In the virus-mediated focal expression of PDGFs in paper IV we observe opposite effects of the 
PDGFR-beta agonists PDGF-B and -D, and this could lead to speculation on different receptor 
specificities. In this system, the availability of PDGFR-alpha responding cells is not limiting: the 
epicardium is a stable source (Weeke-Klimp, Bax et al. 2010; Smith, Baek et al. 2011). We, 
however, fail to detect cells co-expressing PDGFR-alpha and PDGFR-beta, and the effect on 
PDGFR-alpha positive cell recruitment is absent in PDGF-B stimulation, whilst the effect on 
injury extension goes in the opposite direction compared to the other PDGFR-alpha agonists. 
Considering that PDGF-B includes a retention motif, and that its effect could be diffusion 
restricted, there is the possibility that the growth factor would not be surrounded by PDGFR-
alpha responding cells. We wonder if the explanation for PDGF-B ectopic expression reaction 
should be sought with the recently demonstrated effect of PDGFR-beta signalling in 
inflammatory reactions (Olson and Soriano 2011; Stark, Eckart et al. 2013). In this perspective, 
the focal fibrotic effect displayed by the PDGF-B transgenic mutants in paper III could be 
secondary to the strong inflammatory reaction that seems to be mediated by PDGF-B in our 
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virus-driven ectopic expression system in paper IV (mechanisms are reviewed by Kong, Christia 
et al. 2014). 
It is very surprising that PDGF-B and -D have such opposite effects when overexpressed in an 
inflamed tissue (paper IV). Other studies have indicated a contradictory effect of the two 
PDGFR-beta agonists in another cardiac fibrosis model (Fan, Ma et al. 2013) and a specific role 
for PDGF-D in fibroblast differentiation, as well as in metalloproteinases and TGF-beta 
expression (Ponten, Folestad et al. 2005; Zhao, Zhao et al. 2013). The data available on PDGF-
D is still limited, and we don’t know if the two PDGFR-beta agonists compete with each other 
on the same receptor, directing the signalling to different downstream effectors. 
It is not the first time that PDGF signalling is known to have a positive effect on wound healing 
and tissue recovery (Zymek, Bujak et al. 2006), and our study in paper IV would suggest PDGF-
D as possible target for future therapeutic developments in injury-driven inflammation 
treatments. 
Our experimental design was based on previous experience on VEGF overexpression (Huusko, 
Merentie et al. 2010), and, given the short life of the viral cDNA, we decided to analyse the 
samples after two weeks from expression induction. The inflammatory reaction is still ongoing at 
this time point, and it would be very interesting to analyse the samples at a later stage, after the 
inflammation resolution, to record the final fibrotic outcome of the injuries. 
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5 CONCLUDING OBSERVATIONS 
 
The work presented in this thesis adds a small share of intelligence to the complex field of 
PDGF signalling. 
The results obtained during the course of the studies reported identify a key role for PDGFR-
alpha in second heart field-derived cells differentiation and fate determination, during cardiac 
development. With the examination of the physiological function of the retention motif of 
PDGF-A, we were able to determine the prevalence of a long range signalling for PDGFR-alpha, 
unlike other receptors of the family, PDGFR-beta and VEGFR2. Our data recognizes PDGFR-
alpha positive cells as the main players in cardiac fibrosis induced by excessive PDGF signalling 
during myocardial development. PDGFR-alpha signalling appears to be responsible for 
fibroblast recruitment and involved in extracellular matrix deposition. When stimulated in an 
inflammatory context, on the other hand, PDGFR-alpha positive cells seem to play an interesting 
role in tissue recovery. 
The interpretation of the data has sometimes been elusive, especially when the outcome of the 
experiments contrasted with previous knowledge and results. The tools at our disposal, however, 
made the observations solid enough to start some very interesting discussions, often raising more 
questions than they answered. It seems that the more we dig into PDGF signalling, the more we 
grasp the extent of our lack of knowledge in the field. This is probably true for the majority of 
the biological fields, and it’s what keeps us interested and engaged. 
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